$CANLF - Cannabis Technologies Appoints Dr. Tarek
Post# of 229
Posted On: 06/10/2014 6:33:50 AM
$CANLF - Cannabis Technologies Appoints Dr. Tarek S. Mansour, Ph.D. to Scientific Advisory Board
Vancouver, BC - June 10, 2014- Cannabis Technologies Inc. (the company) (CSE: CAN; OTCQB: CANLF) announces today that Tarek Mansour, Ph.D., a veteran executive of the Life Science sector, has joined its Scientific Advisory Board. Dr. Mansour has over 26 years of experience in drug discovery and development with senior leadership and management positions within the biotechnology and pharmaceutical sector.
"We are delighted to welcome Dr. Mansour as a scientific advisor to the Company," said Craig Schneider, President & CEO. "Dr. Mansour is a distinguished R&D executive with the experience of drug development discovery to commercialization. His experience and expertise in both biotechnology and pharmaceutical will be instrumental in guiding our strategic initiatives."
Dr. Mansour's industrial career started in 1989 with BioChem Pharma in Quebec; after which he joined Wyeth-Ayerst in 1997 as Assistant Vice-President to direct the medicinal chemistry efforts at the site in Pearl River, NY. In 2009, his responsibilities were expanded to head the Chemical Sciences Department at four discovery sites in the USA, as well as CRO support in India. After the Wyeth acquisition by Pfizer in 2009, Dr. Mansour was responsible for transition of staff and projects to the Pfizer pipeline. Subsequently, in 2010 he became the Executive Vice-President of R&D for Xenon Pharmaceuticals in British Columbia, Canada until early 2013. In mid 2013, Dr. Mansour became the Founder and Chief Executive Officer of Sabila Biosciences LLC, New York.
Dr. Mansour's expertise spans multiple therapeutic areas including anti-infectives, oncology, inflammatory, metabolic, cardiovascular and pain. Under his leadership, several compounds have progressed to various stages of clinical evaluation including FDA approvals and late stage development. Amongst these candidates are Epivir, Zeffix, Troxatyl, Bosulif, Neratinib and PFE384.
Dr. Mansour received a B.S. degree in Chemistry from the American University of Beirut, Lebanon (1977), M.Sc. in Chemistry from the University of Manchester Institute of Science and Technology, U.K. (1979), a Ph.D. degree from the University of Missouri-Columbia, U.S.A. (1982) and a diploma in Applied Management from McGill University, Canada (1993). Following postdoctoral tenure at the University of Ottawa, Dr. Mansour moved to McGill University in 1985 as a research associate in the Immunomedicinal Chemistry Chair.
About Cannabis Technologies ("CTI"
CTI is a biopharmaceutical drug discovery and development company uniquely focused on the pharmacology and therapeutic potential of cannabinoids.
CTI is utilizing its proprietary "Cannabinoid Drug Design Platform" to identify new bioactive compounds within the marijuana plant that interact with certain genes responsible for specific diseases.
Our extensive research and intellectual properties will initially be focused on the development of several new cannabinoid based treatments for Ocular, Cancer & Angiogenesis, and Inflammation, Pain.
ON BEHALF OF THE BOARD
"Craig Schneider"
President and CEO
For further information, please visit the company's website at www.cannabis-tech.com
Cannabis Technologies Inc.
Craig Schneider
President and Chief Executive Officer
Tel: 604.669.7207
Fax: 604.683.2506
info@cannabis-tech.com / www.cannabis-tech.com
Vancouver, BC - June 10, 2014- Cannabis Technologies Inc. (the company) (CSE: CAN; OTCQB: CANLF) announces today that Tarek Mansour, Ph.D., a veteran executive of the Life Science sector, has joined its Scientific Advisory Board. Dr. Mansour has over 26 years of experience in drug discovery and development with senior leadership and management positions within the biotechnology and pharmaceutical sector.
"We are delighted to welcome Dr. Mansour as a scientific advisor to the Company," said Craig Schneider, President & CEO. "Dr. Mansour is a distinguished R&D executive with the experience of drug development discovery to commercialization. His experience and expertise in both biotechnology and pharmaceutical will be instrumental in guiding our strategic initiatives."
Dr. Mansour's industrial career started in 1989 with BioChem Pharma in Quebec; after which he joined Wyeth-Ayerst in 1997 as Assistant Vice-President to direct the medicinal chemistry efforts at the site in Pearl River, NY. In 2009, his responsibilities were expanded to head the Chemical Sciences Department at four discovery sites in the USA, as well as CRO support in India. After the Wyeth acquisition by Pfizer in 2009, Dr. Mansour was responsible for transition of staff and projects to the Pfizer pipeline. Subsequently, in 2010 he became the Executive Vice-President of R&D for Xenon Pharmaceuticals in British Columbia, Canada until early 2013. In mid 2013, Dr. Mansour became the Founder and Chief Executive Officer of Sabila Biosciences LLC, New York.
Dr. Mansour's expertise spans multiple therapeutic areas including anti-infectives, oncology, inflammatory, metabolic, cardiovascular and pain. Under his leadership, several compounds have progressed to various stages of clinical evaluation including FDA approvals and late stage development. Amongst these candidates are Epivir, Zeffix, Troxatyl, Bosulif, Neratinib and PFE384.
Dr. Mansour received a B.S. degree in Chemistry from the American University of Beirut, Lebanon (1977), M.Sc. in Chemistry from the University of Manchester Institute of Science and Technology, U.K. (1979), a Ph.D. degree from the University of Missouri-Columbia, U.S.A. (1982) and a diploma in Applied Management from McGill University, Canada (1993). Following postdoctoral tenure at the University of Ottawa, Dr. Mansour moved to McGill University in 1985 as a research associate in the Immunomedicinal Chemistry Chair.
About Cannabis Technologies ("CTI"
CTI is a biopharmaceutical drug discovery and development company uniquely focused on the pharmacology and therapeutic potential of cannabinoids.
CTI is utilizing its proprietary "Cannabinoid Drug Design Platform" to identify new bioactive compounds within the marijuana plant that interact with certain genes responsible for specific diseases.
Our extensive research and intellectual properties will initially be focused on the development of several new cannabinoid based treatments for Ocular, Cancer & Angiogenesis, and Inflammation, Pain.
ON BEHALF OF THE BOARD
"Craig Schneider"
President and CEO
For further information, please visit the company's website at www.cannabis-tech.com
Cannabis Technologies Inc.
Craig Schneider
President and Chief Executive Officer
Tel: 604.669.7207
Fax: 604.683.2506
info@cannabis-tech.com / www.cannabis-tech.com
(0)
(0)